once monthly glp 1 agonist We have dosed the first participants in VESPER-6, the latest Phase 3 trial of our lead investigational medicine in obesity. It is the next of around 20 pivotal studies we are starting GLP-1 Antagonists Increase Plan Drug

10.1001/jama.2020.21899 61 SterlingJ.HuaP.DunaiefJ

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline Solubility: 2.5 mg/mL (1.76 mM)

Evidence from Clinical Trials on Weight Loss and Body Composition Liraglutide-based clinical evidence from the SCALE (Satiety and Clinical Adiposity-Liraglutide Evidence) trials (NCT01272219 and NCT01272232), which included older adults within the adult study population, reported that a 56-week intervention with liraglutide 3 mg/day as an adjunct to lifestyle modification resulted in significant weight loss compared with placebo [41, 42]

Guidelines suggest the additional use of DPP-4 inhibitors after metformin failure in patients that do not require antidiabetic therapy with proven cardiovascular benefit

If the solution remains cloudy or contains visible particulates after 15 minutes, the peptide may have degraded during shipping or storage